Stock MRVL MARVEL BIOSCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Marvel Biosciences Corp.

Equities

MRVL

CA57384M1077

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 11:11:00 2024-05-01 EDT 		5-day change 1st Jan Change
0.155 CAD 0.00% Intraday chart for Marvel Biosciences Corp. +14.81% +93.75%
03-26 Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
03-25 Marvel Biosciences Announces Positive Interim Results For MB-204 MT

Valuation

Fiscal Period: Juli 2021 2022 2023
Capitalization 1 7.821 3.152 3.183
Enterprise Value (EV) 1 5.428 2.559 3.626
P/E ratio -1.4 x -1.09 x -1.38 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA -4.35 x -1.02 x -1.65 x
EV / FCF -6,572,421 x -2,122,182 x -8,376,629 x
FCF Yield -0% -0% -0%
Price to Book 3.32 x 16.1 x -1.85 x
Nbr of stocks (in thousands) 32,586 37,086 39,786
Reference price 2 0.2400 0.0850 0.0800
Announcement Date 21-11-16 22-11-23 23-11-28
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: July 2019 2020 2021 2022 2023
Net sales - - - - -
EBITDA 1 -0.2074 -1.018 -1.249 -2.506 -2.193
EBIT 1 -0.2077 -1.018 -1.249 -2.506 -2.193
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -0.2084 -1.019 -3.191 -2.554 -2.291
Net income 1 -0.2084 -0.9557 -3.039 -2.554 -2.291
Net margin - - - - -
EPS - -0.1297 -0.1717 -0.0780 -0.0578
Free Cash Flow - -0.2193 -0.8258 -1.206 -0.4329
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 21-03-16 21-03-16 21-11-16 22-11-23 23-11-28
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Juli 2019 2020 2021 2022 2023
Net Debt 1 0.16 - - - 0.44
Net Cash position 1 - 0.2 2.39 0.59 -
Leverage (Debt/EBITDA) -0.7639 x - - - -0.2022 x
Free Cash Flow - -0.22 -0.83 -1.21 -0.43
ROE (net income / shareholders' equity) - 2,133% -246% -200% 301%
ROA (Net income/ Total Assets) - -429% -56.5% -92.6% -173%
Assets 1 - 0.2229 5.381 2.758 1.326
Book Value Per Share - 0.0100 0.0700 0.0100 -0.0400
Cash Flow per Share - 0.0200 0.0700 0.0200 0.0100
Capex 1 0 - - - -
Capex / Sales - - - - -
Announcement Date 21-03-16 21-03-16 21-11-16 22-11-23 23-11-28
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MARVEL BIOSCIENCES CORP. Stock Marvel Biosciences Corp.
+93.75% 4.49M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.33% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.33% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.48% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.54% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.68% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+13.17% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.87% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MRVL Stock
  4. Financials Marvel Biosciences Corp.